[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610885":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":43,"responsibleParty":45,"collaborators":43,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":43,"eligibilityCriteria":53,"healthyVolunteers":50,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":43,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":67,"whyStopped":43,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},{"fullName":5,"class":6},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dextrose Prolotherapy","EXPERIMENTAL","Participants in this group will receive dextrose prolotherapy twice, at two-week intervals.\n\nA 5 mL syringe will be prepared with 2.5 mL of 30% dextrose, 2 mL of isotonic saline, and 0.5 mL of 2% lidocaine (final 15% dextrose solution).\n\nInjections will be administered into seven points around the plantar fascia origin and insertion under aseptic conditions.",[13],"Procedure: Dextrose Prolotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Extracorporeal Shock Wave Therapy (ESWT)","ACTIVE_COMPARATOR","Participants in this group will receive extracorporeal shock wave therapy (ESWT) twice per week for a total of four sessions.\n\nThe treatment will be applied to the plantar fascia insertion using a standard clinical ESWT device following manufacturer guidelines.",[19],"Device: Extracorporeal Shock Wave Therapy (ESWT)",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Participants in this group will receive dextrose prolotherapy twice, at two-week intervals.\n\nA 5 mL syringe containing 2.5 mL of 30% dextrose, 2 mL isotonic saline, and 0.5 mL 2% lidocaine (final 15% dextrose solution) will be injected into seven points around the plantar fascia origin under aseptic conditions.",[9],[26],"Prolotherapy Injection",{"type":28,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"DEVICE","Participants in this group will receive extracorporeal shock wave therapy (ESWT) twice per week for a total of four sessions.\n\nThe treatment will be applied to the plantar fascia insertion area using a standard clinical shock wave therapy device.\n\nEnergy level, frequency, and pulse count will be set according to manufacturer recommendations and standard clinical protocols.",[15],[32],"Shock Wave Therapy",[34],{"name":35,"affiliation":36,"role":37},"ZEYNEP KARAKUZU GÜNGÖR, MD","Kanuni Sultan Süleyman Training and Research Hospital, Istanbul","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"ZEYNEP KARAKUZU GÜNGÖR","CONTACT","+905077750375",null,"zeynepkarakuzu@hotmail.com.tr",{"type":37,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"Zeynep Karakuzu Güngör","Physical Medicine and Rehabilitation","100610885","comparison-of-the-effectiveness-of-dextrose-prolotherapy-and-extracorporeal-shock-wave-therapy-eswt-in-plantar-fasciitis-100610885",false,"NCT07233395","Comparison of the Effectiveness of Dextrose Prolotherapy and Extracorporeal Shock Wave Therapy (ESWT) in Plantar Fasciitis","Inclusion Criteria:\n\n* Diagnosis of plantar fasciitis\n\nAges 18 to 75 years\n\nBoth male and female participants\n\nHeel pain localized to the medial calcaneal tubercle for more than 3 months\n\nMorning first-step pain and pain increasing with daily loading\n\nWillingness to participate and provide written informed consent\n\nPatients presenting to Kanuni Sultan Süleyman Training and Research Hospital\n\nExclusion Criteria:\n\nCardiac pacemaker\n\nType 1 or Type 2 diabetes mellitus\n\nHistory of inflammatory rheumatic disease\n\nBleeding disorders\n\nUse of anticoagulant medications other than aspirin\n\nAllergy to dextrose\n\nPrevious foot or ankle surgery\n\nPeripheral neuropathy\n\nS1 radiculopathy in the same extremity\n\nLocal corticosteroid injection to the plantar fascia within the last 3 months\n\nESWT applied to the plantar fascia within the last 3 months\n\nPhysical therapy applied to the foot\u002Fankle in the last 3 months\n\nCognitive dysfunction\n\nActive infection at the planned injection site\n\n\\-","ALL","18 Years","75 Years",{"count":58,"type":59},60,"ESTIMATED","INTERVENTIONAL",[62],"NA","Plantar fasciitis is a degeneration of the plantar aponeurosis and is the most common cause of heel pain (11-15%). Although seen in both sexes, plantar fasciitis is more common in women, usually unilateral and bilateral in 30% of cases . The most widely accepted view regarding the formation of plantar fasciitis is that it is a degenerative process caused by myxoid degeneration, microtears, collagen necrosis, and angiofibroblastic hyperplasia, resulting from repetitive microtrauma to the plantar fascia, particularly at the calcaneal insertion site. It is not inflammatory . The purpose of this study was to compare the effectiveness of prolotherapy, a regenerative treatment, and ESWT in the treatment of plantar fasciitis.",[65],"Plantar Fasciitis",[9,15,47],"NOT_YET_RECRUITING","2025-11-14",{"date":70,"type":71},"2025-11-18","ACTUAL",{"date":73,"type":59},"2025-11-15",{"date":75,"type":59},"2026-03-15",{"name":5,"class":6}]